STOCK TITAN

Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Rhea-AI Summary
Emergent BioSolutions Inc. (NYSE: EBS) will hold a conference call on March 6, 2024, to discuss financial results for Q4 and full year 2023. Newly appointed CEO Joseph C. Papa will provide remarks.
Positive
  • None.
Negative
  • None.

GAITHERSBURG, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, March 6, 2024, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2023. Emergent’s newly appointed president and CEO, Joseph C. Papa, will provide remarks.

Conference Call Information
Participants can access the conference call live via webcast from the Investors page of Emergent’s website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.

A replay of the call can be accessed from the Investors page of Emergent’s website.

About Emergent BioSolutions
At Emergent, our mission is to protect and enhance life. For 25 years, we’ve been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our website and follow us on LinkedInX (formerly Twitter), and Instagram.

Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com

Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com


Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, March 6, 2024, at 5:00 pm eastern time.

Newly appointed president and CEO, Joseph C. Papa, will provide remarks during the conference call.

Participants can access the conference call live via webcast from the Investors page of Emergent’s website or register in advance to participate via telephone.

A replay of the call can be accessed from the Investors page of Emergent’s website.
Emergent Biosolutions Inc

NYSE:EBS

EBS Rankings

EBS Latest News

EBS Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
US
Gaithersburg

About EBS

emergent biosolutions is a global life sciences company dedicated to one simple mission—to protect and enhance life. we develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. through our work, we envision protecting and enhancing 50 million lives with our products by 2025. additional information about the company may be found at www.emergentbiosolutions.com. follow us @emergentbiosolu and @life_at_emergent